TWIST BIOSCIENCE CORP
TWSTNASDAQTrading Snapshot
- Day Range
- $159.70 β $178.27
- 52-Week Range
- $23.30 β $219.71
- Volume (shares)
- 196,915
- Avg Volume (shares)
- β
- Shares Outstanding
- 65.8M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $377M
- Last Q Revenue
- $118M
- P/E Ratio
- -65.4
- P/S Ratio
- 22.1x
- EPS (TTM)
- $-2.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.2%
TWIST BIOSCIENCE CORP
TWSTAbout TWIST BIOSCIENCE CORP
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.